An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

Matthew P R Berry, Christine M Graham, Finlay W McNab, Zhaohui Xu, Susannah A A Bloch, Tolu Oni, Katalin A Wilkinson, Romain Banchereau, Jason Skinner, Robert J Wilkinson, Charles Quinn, Derek Blankenship, Ranju Dhawan, John J Cush, Asuncion Mejias, Octavio Ramilo, Onn M Kon, Virginia Pascual, Jacques Banchereau, Damien Chaussabel, Anne O'Garra, Matthew P R Berry, Christine M Graham, Finlay W McNab, Zhaohui Xu, Susannah A A Bloch, Tolu Oni, Katalin A Wilkinson, Romain Banchereau, Jason Skinner, Robert J Wilkinson, Charles Quinn, Derek Blankenship, Ranju Dhawan, John J Cush, Asuncion Mejias, Octavio Ramilo, Onn M Kon, Virginia Pascual, Jacques Banchereau, Damien Chaussabel, Anne O'Garra

Abstract

Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major cause of morbidity and mortality worldwide. Efforts to control it are hampered by difficulties with diagnosis, prevention and treatment. Most people infected with M. tuberculosis remain asymptomatic, termed latent TB, with a 10% lifetime risk of developing active TB disease. Current tests, however, cannot identify which individuals will develop disease. The immune response to M. tuberculosis is complex and incompletely characterized, hindering development of new diagnostics, therapies and vaccines. Here we identify a whole-blood 393 transcript signature for active TB in intermediate and high-burden settings, correlating with radiological extent of disease and reverting to that of healthy controls after treatment. A subset of patients with latent TB had signatures similar to those in patients with active TB. We also identify a specific 86-transcript signature that discriminates active TB from other inflammatory and infectious diseases. Modular and pathway analysis revealed that the TB signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-gamma and type I IFN-alphabeta signalling. Comparison with transcriptional signatures in purified cells and flow cytometric analysis suggest that this TB signature reflects changes in cellular composition and altered gene expression. Although an IFN-inducible signature was also observed in whole blood of patients with systemic lupus erythematosus (SLE), their complete modular signature differed from TB, with increased abundance of plasma cell transcripts. Our studies demonstrate a hitherto underappreciated role of type I IFN-alphabeta signalling in the pathogenesis of TB, which has implications for vaccine and therapeutic development. Our study also provides a broad range of transcriptional biomarkers with potential as diagnostic and prognostic tools to combat the TB epidemic.

Figures

Figure 1. A distinct whole blood 393-gene…
Figure 1. A distinct whole blood 393-gene transcriptional signature of active TB
393-transcripts differentially expressed in whole blood of active and latent TB patients and healthy controls a, Test Set. b, Validation Set (SA) profiles, ordered by hierarchical clustering (Spearman correlation with average linkage) creating a condition tree, upper horizontal edge of heatmap; study grouping (clinical phenotype) coloured blocks at each profile base. Heatmap rows = genes, columns = participants. c, Profiles were grouped according to radiographic extent of disease and the mean “Molecular Distance to Health” compared between groups (Methods) (Kruskal-Wallis ANOVA, Dunn's multiple comparison, *** = p <0.0001). d, Active TB patients at 0, 2 and 12 months after initiation of anti-mycobacterial treatment. The mean “Molecular Distance to Health” for each timepoint was compared (Friedman's repeated measures test, Dunn's multiple comparison). Horizontal bars indicate the median, 5th and 95th percentiles.
Figure 2. A distinct whole blood 86-gene…
Figure 2. A distinct whole blood 86-gene transcriptional signature of active TB is distinct from other diseases
a, Comparison of 86-gene signature in patients with TB and other diseases normalized to their own controls; TB (Training, n=13; Control, n=12), TB (SA, n=20; Control = 12), Group A Streptococcus (Strep; n=23; Control=12), Staphylococcus (Staph; n=40; Control= 12), Still's disease (Still; n=31; Control=22), Adult (SLE; n=29; Control= 16) and paediatric SLE (pSLE; n=49; Control=11) patients. b, Expression levels of 86 gene signature after 2 and 12 months of treatment in TB patients.
Figure 3. Whole blood transcriptional signature of…
Figure 3. Whole blood transcriptional signature of active TB reflects distinct changes in cellular composition and gene expression
a, Gene expression (disease versus healthy controls) of TB (Test Set) and different diseases mapped within a pre-defined modular framework. Spot intensity (red = increased, blue = decreased) indicates transcript abundance. Functional interpretations previously determined by unbiased literature profiling shown by colour-coded grid. Whole blood (Test Set active TB patients and controls) analysed by flow cytometry for (b) CD3+CD4+ and CD3+CD8+ T cells and CD19+CD20+ B cells (c) CD14+ monocytes, CD14+CD16+ inflammatory monocytes and CD16+ neutrophils. Error bars = median, ** = p<0.01, * = p<0.05, Mann-Whitney test.
Figure 4. Interferon-inducible gene expression in active…
Figure 4. Interferon-inducible gene expression in active TB
Ingenuity Pathways analysis canonical pathway for interferon signalling symbol indicates gene function (legend on right). Transcripts over-represented in Test Set active TB patients shaded red a, Type II IFN-γ. b, Type I IFNαβ signalling. Transcript abundance of representative IFN-inducible genes in active TB (Test Set) from c, whole blood, d, separated blood leucocyte population. Transcript abundance/expression is normalised to the median of the healthy controls.

References

    1. Dye C, Floyd K, Uplekar M. WHO report. World Health Organization; Geneva: 2008.
    1. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med. 2005;11:S33–44.
    1. Barry CE, 3rd, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845–55.
    1. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27:393–422.
    1. Young DB, Perkins MD, Duncan K, Barry CE., 3rd Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest. 2008;118:1255–65.
    1. Ardura MI, et al. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One. 2009;4:e5446.
    1. Chaussabel D, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29:150–64.
    1. Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol. 28:535–71.
    1. Ramilo O, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood. 2007;109:2066–77.
    1. Falk A, O'Connor JB. Classification of pulmonary tuberculosis: Diagnosis standards and classification of tuberculosis. National tuberculosis and respiratory disease association. 1969;12:68–76.
    1. Pankla R, et al. Genomic Transcriptional Profiling Identifies a Candidate Blood Biomarker Signature for the Diagnosis of Septicemic Melioidosis. Genome Biol. 2009;10:R127.
    1. Allantaz F, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204:2131–44.
    1. Baechler EC, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610–5.
    1. Bennett L, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711–23.
    1. Beck JS, Potts RC, Kardjito T, Grange JM. T4 lymphopenia in patients with active pulmonary tuberculosis. Clin Exp Immunol. 1985;60:49–54.
    1. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669–92.
    1. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581–620.
    1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93–129.
    1. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5:675–87.
    1. Manca C, et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res. 2005;25:694–701.
    1. Ordway D, et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol. 2007;179:522–31.
    1. Manca C, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A. 2001;98:5752–7.
    1. Cooper AM, Pearl JE, Brooks JV, Ehlers S, Orme IM. Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun. 2000;68:6879–82.
    1. Telesca C, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect. 2007;54:e223–6.
    1. Eum SY, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary tuberculosis. Chest. 2009
    1. Eruslanov EB, et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun. 2005;73:1744–53.
    1. Jacobsen M, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med. 2007;85:613–21.
    1. Mistry R, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis. 2007;195:357–65.
    1. Salisbury D, Ramsay M. Immunization against infectious diseases - the Green Book. D.O.Health. The Stationery Office; London: 2006. pp. 391–408.
    1. National Institute for Health and Clinical Excellence . Royal College of Physicians; UK: 2006.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner